Wanbury Limited is placing a spotlight on leadership continuity as it greenlights the re-appointment of a long-standing insider to its top executive tier. The Board, after deliberations on August 11, 2026, approved the re-appointment of Mohan Kumar Rayana as Whole-time Director for a five-year term, with effect from August 21, 2026, subject to the approval of Wanbury’s shareholders and applicable regulators. The move underscores Wanbury’s preference for steady governance and strategic stewardship as it charts its course through a competitive pharmaceutical landscape.
Rayana’s deep-rooted association with Wanbury stretches back to the company’s early years, positioning him as a stabilizing force within the leadership team. A B. Pharm graduate from the University of Mumbai, he has spent over two decades guiding Wanbury through business strategy, general management, talent development, acquisitions, and capital considerations. Colloquially described as a business and management advisor to Wanbury for more than 25 years, Rayana’s sustained involvement and institutional knowledge are viewed as a valuable asset for the company’s growth ambitions and operational execution.
The board’s decision reflects Wanbury’s emphasis on continuity and internal leadership as it seeks to strengthen its presence in the pharma sector while navigating capital considerations and regulatory expectations. If shareholders give their nod, Rayana will continue to helm the executive duties for a period of five years, aiding in strategic initiatives, governance, and the integration of plans that have been shaping Wanbury’s trajectory since its inception.